Stereotaxis Inc. (STXS) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Stereotaxis Inc. (NYSE: STXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.91 (-6.21% 1D, market cap $91.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STXS ranks #946 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), STXS carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 52.7%, and ROIC of -35.0%. By comparison, NRXS (Neuraxis Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $94.8M) and VANI (Vivani Medical Inc.) posts a E grade (34/100 RQD, P/E 3.9x, ROIC -35.0%, cap $102.8M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).
Per STXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001289340), Stereotaxis Inc. generated $32.4M in revenue (+20.3% YoY), -$21.6M in net income, and -$13.7M in free cash flow against $52.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While STXS currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.22) and Max Pain ($0.96) forces dealer call-delta covering toward $3.08.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Stereotaxis Inc. (STXS) dropped -6.21% to $0.91, trading at 5% of its 52-week range ($0.81 – $2.93). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technologyTechnologies will be presented at TCT 2026 in the Canon booth TUSTIN, Calif. and ST. LOUIS, Oct
Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technologyTechnologies will be presented at TCT 2026 in the Canon boothTUSTIN, Calif. and ST. LOUIS,
Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in LatviaFirst procedures successfully treat
Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in LatviaFirst procedures successfully
ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financi
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on STXS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for STXS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Stereotaxis Inc. (STXS) ranks #946 by composite RQD confidence (30/100, grade E) and #674 by equity capitalization ($91.2M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with STXS at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| STXS
ACTIVE
Stereotaxis Inc. | E | 30/100 | — | 52.7% | -35.0% | -6.21% | $91.2M | Benchmark Subject |
| NRXS Neuraxis Inc. | E | 32/100 | — | 84.2% | -35.0% | -0.26% | $94.8M | /nrxs-vs-stxs → |
| VANI Vivani Medical Inc. | E | 34/100 | 3.9x | — | -35.0% | 0.00% | $102.8M | /vani-vs-stxs → |
| HYPR Hyperfine Inc. (Class A) | D | 45/100 | — | 49.8% | -35.0% | -5.23% | $78.9M | /hypr-vs-stxs → |
| OM Outset Medical Inc. | D- | 35/100 | — | 39.1% | -28.0% | -3.46% | $78.8M | /om-vs-stxs → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Stereotaxis Inc. (STXS) reported GAAP revenue of $32.4M (+20.3% vs. FY2024 revenue of $26.9M , and +20.9% cumulative change since FY2023) , GAAP net income of -$21.6M, operating cash flow of -$13.7M, and free cash flow of -$13.7M (-61.1% YoY). On the balance sheet, STXS closed FY2025 with $52.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $32.4M | -$21.6M | -$13.7M | -$13.7M | $52.3M | — |
| FY2024 (FY) | 2024-12-31 | $26.9M | -$24.0M | -$8.5M | -$8.5M | $46.7M | — |
| FY2023 (FY) | 2023-12-31 | $26.8M | -$20.7M | -$9.1M | -$9.1M | — | — |
As of 2026-11-01, Stereotaxis Inc. (NYSE: STXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.91 (-6.21% 1D, market cap $91.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STXS ranks #946 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), STXS carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 52.7%, and ROIC of -35.0%. By comparison, NRXS (Neuraxis Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $94.8M) and VANI (Vivani Medical Inc.) posts a E grade (34/100 RQD, P/E 3.9x, ROIC -35.0%, cap $102.8M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).
Per STXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001289340), Stereotaxis Inc. generated $32.4M in revenue (+20.3% YoY), -$21.6M in net income, and -$13.7M in free cash flow against $52.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
STXS last traded at $0.91 (-6.21% on volume of 812,876 shares), positioning the stock -25.41% below its 50-day simple moving average ($1.22) and -46.78% below its 200-day simple moving average ($1.71). Across its 52-week range of $0.81 to $2.93, STXS sits at the 4.7% percentile with a 14-day RSI of 21.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.02).
Why STXS Stock dropped -6.21% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.